Protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19
10.12092/j.issn.1009-2501.2020.04.011
- VernacularTitle: 新型冠状病毒肺炎临床试验的受试者保护
- Author:
Zhengfu ZHANG
1
Author Information
1. Center for Food and Drug Inspection of NMPA
- Publication Type:Journal Article
- Keywords:
Clinical trials;
COVID-19;
Protection of subjects' legal rights
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(4):421-425
- CountryChina
- Language:Chinese
-
Abstract:
Since December 2019, COVID-19 has been found in Wuhan, Hubei Province of China, which has spread in many countries and regions around the world. A large number of clinical trials have been launched in China aiming to find safe and effective drugs and treatments.The protection of subjects' legal rights, welfare and safety should be superior to the consideration of scientific and social benefits. Therefore, all parties involved in clinical trials should take corresponding measures to protect subjects' legal rights, welfare and safety. This paper discussed about the protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19 from all aspects of the clinical trials, aiming to provide reference for all parties involved in clinical trials and basic ideas for the protection of subjects' legal rights, welfare and safety in clinical trials of emergencies.
